Our study highlights the heightened anti-tumor efficacy of anti-BCMA-CAR3 T cells against BCMA-expressing MM cell lines in vitro when compared to anti-BCMA-CAR2 T cells. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.